The NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

PD-1 inhibitors have revolutionised cancer treatment over the last decade, with their success attributed to Keytruda and ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

One upcoming decision—on a perioperative PD-1 regimen for lung cancer—comes as the FDA considers an overhaul of trial designs in this treatment setting.

Nivolumab, an immune checkpoint inhibitor lauded for its groundbreaking approach to cancer treatment, marked its 10th anniversary this month since its release by Ono Pharmaceutical Co under the brand ...

As of now, Bristol Myers Squibb has registered a Year-to-Date (YTD) stock performance of +1.48%. This figure starkly contrasts with the S&P 500’s impressive YTD performance of +20.45%. While BMY’s ...

A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a ...

While it is highly effective in treating multiple types of cancer, its extremely high price has reignited the debate over how ...

Nivolumab, an immune checkpoint inhibitor lauded for its groundbreaking approach to cancer treatment, marked its 10th ...

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in esophageal cancer with PD-L1 ...

Tom Nolan reviews this week’s research Before 2011, when checkpoint inhibitor treatments became available, the median survival for people with advanced melanoma was 11 months. The final results of the ...